# PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma

> **NCT05466474** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** Tislelizumab Injection

## Key facts

- **NCT ID:** NCT05466474
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-30
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05466474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05466474, "PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05466474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*